Lenzilumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | human colony stimulating factor 2 |
| Clinical data | |
| Other names | KB003 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6474H10024N1748O2010S42 |
| Molar mass | 145.85 kDa g·mol−1 |
Lenzilumab (INN) (alternative identifier KB003)[1] is a humanized monoclonal antibody (class IgG1 kappa)[2] that targets colony stimulating factor 2 (CSF2)/granulocyte-macrophage colony stimulating factor (GM-CSF) designed for the treatment of chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML).[3][4][5] In vitro studies on human cells have demonstrated that Lenzilumab can induce sensitivity in myeloid and monocytic cells suggesting the antibody's applicability in CMML and JMML indications.[6]
This drug is under development by KaloBios Pharmaceuticals Inc. and as of 2017 is currently undergoing clinical trials for CMML.[7][8] Prior to application in treating CMML, Lenzilumab was assessed for use in treating inadequately controlled asthma[9] and rheumatoid arthritis.[10]
References
- ^ "Lenzilumab - AdisInsight". adisinsight.springer.com. Retrieved 2017-03-24.
- ^ "Anti-Human CSF2 Therapeutic Antibody (lenzilumab) - Creative Biolabs". www.creativebiolabs.net. Retrieved 2017-03-24.
- ^ "Lenzilumab :: KaloBios Pharmaceuticals, Inc. (KBIO)". KaloBios Pharmaceuticals, Inc. Retrieved 2017-03-24.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lenzilumab, American Medical Association.
- ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
- ^ Padron, Eric; Painter, Jeffrey S.; Kunigal, Sateesh; Mailloux, Adam W.; McGraw, Kathy; McDaniel, Jessica M.; Kim, Eunhee; Bebbington, Christopher; Baer, Mark (2013-06-20). "GM-CSF–dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia". Blood. 121 (25): 5068–5077. doi:10.1182/blood-2012-10-460170. ISSN 0006-4971. PMC 4347259. PMID 23632888.
- ^ Inc., KaloBios Pharmaceuticals. "KaloBios Announces First Patient Dosed in Phase 1 Study of Lenzilumab for the Treatment of Chronic Myelomonocytic Leukemia". GlobeNewswire News Room. Retrieved 2017-03-24.
{{cite news}}:|last=has generic name (help) - ^ "Study of Lenzilumab (KB003) in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML) - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2017-03-24.
- ^ "Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2017-03-24.
- ^ "Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2017-03-24.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |